Glaucoma Trial, Recruiting NCT07355491 Sponsor: Intalight, Inc Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT07355491
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

I'll present the eligibility criteria for each of the four groups in this trial separately, as each group has different requirements.


GROUP 1: Normal (Healthy) Eyes Group

Who might be able to join this trial:

  • People who are 22 years of age or older at the time of signing the consent form
  • People who are able to understand and willing to sign a written consent form agreeing to take part
  • People whose eyes appear normal during an eye examination at the study visit, checked using a special lens
  • People whose best corrected vision (with glasses or contact lenses if needed) is 20/40 or better in each eye at the study visit

Who may not be able to join:

  • People who are unable to tolerate eye imaging procedures
  • People whose eye imaging cannot produce usable scan results due to cloudiness in the eye or other reasons
  • People who have a health condition or situation that the study doctor believes could put them at significant risk, affect the study results, or make it difficult for them to fully take part
  • People who have any eye disease or condition in either eye, except for cataracts

GROUP 2: Glaucoma Group

Who might be able to join this trial:

  • People who are 22 years of age or older at the time of signing the consent form
  • People who are able to understand and willing to sign a written consent form agreeing to take part
  • People whose best corrected vision (with glasses or contact lenses if needed) is 20/40 or better in the study eye
  • People who have had a visual field test showing signs of glaucoma-related vision loss, either within the past year or on the day of the study visit — specifically, a cluster of three or more weak spots in expected areas of the visual field, with at least one being significantly weak, or a result flagged as "outside normal limits" on a specific glaucoma test
  • People who show physical signs of glaucoma damage to the optic nerve or the nerve fibre layer around it — such as thinning, narrowing, or notching of the nerve tissue (particularly at the top or bottom of the optic disc, with or without a small bleed), or a noticeable difference in nerve tissue between the two eyes

Who may not be able to join:

  • People who are unable to tolerate eye imaging procedures
  • People whose eye imaging cannot produce usable scan results due to cloudiness in the eye or other reasons
  • People who have a health condition or situation that the study doctor believes could put them at significant risk, affect the study results, or make it difficult for them to fully take part
  • People who do not have a reliable visual field test result from within the past year in the study eye — where "reliable" means the test did not show too many fixation errors, false positives, or false negatives (each must be 33% or lower) (confirm with trial site)

GROUP 3: Retinal Disease Group

Who might be able to join this trial:

  • People who are 22 years of age or older at the time of signing the consent form
  • People who are able to understand and willing to sign a written consent form agreeing to take part
  • People whose best corrected vision (with glasses or contact lenses if needed) is 20/400 or better in the study eye
  • People who have been diagnosed by a study doctor with a retinal condition — this may include conditions such as macular degeneration (including drusen, geographic atrophy, or abnormal blood vessel growth), diabetic macular swelling, diabetic retinopathy, a macular hole, a membrane growing over the macula, central serous retinopathy, blockages in the blood vessels of the eye, or other retinal conditions

Who may not be able to join:

  • People who are unable to tolerate eye imaging procedures
  • People whose eye imaging cannot produce usable scan results due to cloudiness in the eye or other reasons
  • People who have a health condition or situation that the study doctor believes could put them at significant risk, affect the study results, or make it difficult for them to fully take part

GROUP 4: Cornea Group

Who might be able to join this trial:

  • People who are 22 years of age or older at the time of signing the consent form
  • People who are able to understand and willing to sign a written consent form agreeing to take part
  • People who have one of the following corneal (front surface of the eye) conditions: a corneal disease such as Fuchs' dystrophy or similar, keratoconus (a cone-shaped cornea), a corneal transplant, previous laser eye surgery such as LASIK or similar, dry eye syndrome, or a history of wearing contact lenses for more than one year
  • People whose best corrected vision (with glasses or contact lenses if needed) is 20/400 or better in the study eye

Who may not be able to join:

  • People who are unable to tolerate eye imaging procedures
  • People whose eye imaging cannot produce usable scan results due to cloudiness in the eye or other reasons
  • People who have a health condition or situation that the study doctor believes could put them at significant risk, affect the study results, or make it difficult for them to fully take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Micahel Chaglasian, OD, Illinois College of Optometry

Phone: 6198067636

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Intalight, Inc
Registry
ClinicalTrials.gov
Start date
16 December 2025
Est. completion
1 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Agreement results and Precision Results

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov